159 related articles for article (PubMed ID: 11197347)
1. Molecular determinants of non-specific recognition of delta, mu, and kappa opioid receptors.
Filizola M; Villar HO; Loew GH
Bioorg Med Chem; 2001 Jan; 9(1):69-76. PubMed ID: 11197347
[TBL] [Abstract][Full Text] [Related]
2. Differentiation of delta, mu, and kappa opioid receptor agonists based on pharmacophore development and computed physicochemical properties.
Filizola M; Villar HO; Loew GH
J Comput Aided Mol Des; 2001 Apr; 15(4):297-307. PubMed ID: 11349813
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of novel opioid ligands with an azabicyclo[2.2.2]octane skeleton having a 7-amide side chain and their pharmacologies.
Watanabe Y; Kitazawa S; Nemoto T; Hirayama S; Iwai T; Fujii H; Nagase H
Bioorg Med Chem; 2013 Jun; 21(11):3032-50. PubMed ID: 23623711
[TBL] [Abstract][Full Text] [Related]
5. Probing ligand recognition of the opioid pan antagonist AT-076 at nociceptin, kappa, mu, and delta opioid receptors through structure-activity relationships.
Journigan VB; Polgar WE; Tuan EW; Lu J; Daga PR; Zaveri NT
Sci Rep; 2017 Oct; 7(1):13255. PubMed ID: 29038479
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.
Metzger TG; Paterlini MG; Ferguson DM; Portoghese PS
J Med Chem; 2001 Mar; 44(6):857-62. PubMed ID: 11300867
[TBL] [Abstract][Full Text] [Related]
7. 3D-QSAR comparative molecular field analysis on opioid receptor antagonists: pooling data from different studies.
Peng Y; Keenan SM; Zhang Q; Kholodovych V; Welsh WJ
J Med Chem; 2005 Mar; 48(5):1620-9. PubMed ID: 15743203
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.
Peng X; Knapp BI; Bidlack JM; Neumeyer JL
J Med Chem; 2006 Jan; 49(1):256-62. PubMed ID: 16392810
[TBL] [Abstract][Full Text] [Related]
9. Exploring the structure of opioid receptors with homology modeling based on single and multiple templates and subsequent docking: a comparative study.
Bera I; Laskar A; Ghoshal N
J Mol Model; 2011 May; 17(5):1207-21. PubMed ID: 20661609
[TBL] [Abstract][Full Text] [Related]
10. 3D modeling, ligand binding and activation studies of the cloned mouse delta, mu; and kappa opioid receptors.
Filizola M; Laakkonen L; Loew GH
Protein Eng; 1999 Nov; 12(11):927-42. PubMed ID: 10585498
[TBL] [Abstract][Full Text] [Related]
11. Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints.
Pogozheva ID; Lomize AL; Mosberg HI
Biophys J; 1998 Aug; 75(2):612-34. PubMed ID: 9675164
[TBL] [Abstract][Full Text] [Related]
12. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice.
Baker AK; Meert TF
J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687
[TBL] [Abstract][Full Text] [Related]
13. Involvement of mu-, delta- and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats.
Solinas M; Goldberg SR
Psychopharmacology (Berl); 2005 Jun; 179(4):804-12. PubMed ID: 15619107
[TBL] [Abstract][Full Text] [Related]
14. The region in the mu opioid receptor conferring selectivity for sufentanil over the delta receptor is different from that over the kappa receptor.
Zhu J; Xue JC; Law PY; Claude PA; Luo LY; Yin J; Chen C; Liu-Chen LY
FEBS Lett; 1996 Apr; 384(2):198-202. PubMed ID: 8612823
[TBL] [Abstract][Full Text] [Related]
15. A chimeric analysis of the opioid receptor domains critical for the binding selectivity of mu opioid ligands.
Watson B; Meng F; Akil H
Neurobiol Dis; 1996 Feb; 3(1):87-96. PubMed ID: 9173916
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological profiles of selective non-peptidic delta opioid receptor ligands.
Chaturvedi K; Jiang X; Christoffers KH; Chinen N; Bandari P; Raveglia LF; Ronzoni S; Dondio G; Howells RD
Brain Res Mol Brain Res; 2000 Sep; 80(2):166-76. PubMed ID: 11038249
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes.
Lester PA; Traynor JR
Brain Res; 2006 Feb; 1073-1074():290-6. PubMed ID: 16443205
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of a new opioid ligand having the oxabicyclo[3.2.1]octane skeleton using a new rearrangement reaction.
Watanabe A; Fujii H; Nakajima M; Hasebe K; Mochizuki H; Nagase H
Bioorg Med Chem Lett; 2009 May; 19(9):2416-9. PubMed ID: 19349178
[TBL] [Abstract][Full Text] [Related]
19. Opioid receptor types and subtypes: the delta receptor as a model.
Zaki PA; Bilsky EJ; Vanderah TW; Lai J; Evans CJ; Porreca F
Annu Rev Pharmacol Toxicol; 1996; 36():379-401. PubMed ID: 8725395
[TBL] [Abstract][Full Text] [Related]
20. A three-dimensional model of the delta-opioid pharmacophore: comparative molecular modeling of peptide and nonpeptide ligands.
Shenderovich MD; Liao S; Qian X; Hruby VJ
Biopolymers; 2000 Jun; 53(7):565-80. PubMed ID: 10766952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
